Navigation Links
GlaxoSmithKline Donates Scientific Equipment to Advance IDRI's Global Health Mission
Date:10/3/2011

SEATTLE, Oct. 3, 2011 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) announces today that GlaxoSmithKline (GSK) Biologicals Hamilton has donated a broad range of instrumentation and equipment that will assist IDRI as it designs and validates solutions to reduce the burden of disease in the developing world. IDRI will apply the gift as it prepares for clinical trials in the areas of tuberculosis, leishmaniasis, malaria, leprosy, and pandemic influenza.

"We at IDRI view this generous gift by our friends at GSK as a demonstration of confidence that the products IDRI is researching today will soon be making a difference for people worldwide," said H. Stewart Parker, IDRI's Chief Executive Officer.  "GSK's generous donation will enable new health technologies to be deployed for a number of diseases that particularly affect those in low resource settings."

"GSK has seen IDRI's talented scientists develop world-class technologies that have entered into numerous successful clinical trials," said Pamela Sager, Business Support Manager at GSK.  "We believe that the equipment we are giving to IDRI will not only further the world's scientific understanding of infectious diseases, but that this gift will also advance IDRI's global health mission."

GSK acquired the equipment when the company purchased the former Corixa site in Seattle in 2005.

About IDRI
IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty. By integrating capabilities — including early stage drug discovery, preclinical testing, manufacturing, and clinical trials — IDRI strives to create an efficient pathway bringing scientific innovation from the laboratory to the people who need it most.

For more information, go to www.idri.org.
IDRI Contact: media@idri.org, 206-381-0883

About GSK
GlaxoSmithKline:  A Leader in Vaccines
GlaxoSmithKline Biologicals (GSK Biologicals), GlaxoSmithKline's vaccines business, is one of the world's leading vaccine companies and a leader in innovation.   The company is active in the fields of vaccine research, development and production with over 30 vaccines approved for marketing around the world and 20 more in development.

For more information, go to www.gsk.com.


'/>"/>
SOURCE Infectious Disease Research Institute (IDRI)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GlaxoSmithKline CEO and CFO Interviewed on Q2 2011 Results
2. GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older
3. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
4. GlaxoSmithKline Confirms allis Safety Profile
5. Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint
6. GlaxoSmithKline Wins Environmental Stewardship Award
7. GlaxoSmithKline 15th Annual IMPACT Awards Seek Philadelphia Area and Camden Healthcare Nonprofits
8. GlaxoSmithKline Applauds North Carolinas Child Advocates
9. A Statement from GlaxoSmithKline Consumer Healthcare on FDA Regulation of Smokeless Tobacco Products
10. Mylan Granted Temporary Restraining Order Against GlaxoSmithKline and Apotex Prohibiting the Supply, Sale and/or Importing of a Generic Version of Paxil CR
11. GlaxoSmithKline CEO Interviewed On Half-Year and Q2 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 Conference Call and Webcast to ... ) today announced it will release results for the fourth quarter ... ... host a conference call at 4:30 PM ET on Wednesday, February ... full year 2016 financial results and other corporate activities. To participate ...
(Date:1/19/2017)... , Jan. 19, 2017 This report ... current and future scenario of the global market. Large ... opioid consumption. Severe chronic constipation is a major side ... traditional laxatives. Hence, novel targeted therapy has been prescribed ... sufferers, launch of targeted medicines, and growing awareness about ...
(Date:1/19/2017)...  Stealth BioTherapeutics Inc. ( Stealth ), a clinical-stage ... announced new additions to its senior leadership team: ... and Daniel Geffken as interim Chief Financial ... , Pharm.D. has been promoted to Chief Clinical Development ... Doug and Daniel to our management team, as both ...
Breaking Medicine Technology:
(Date:1/20/2017)... Viejo, California (PRWEB) , ... January 20, 2017 , ... ... easy to use inside of Final Cut Pro X," said Christina Austin - CEO ... on the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is Greater than ... the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” ... career as an educator interacting with countless women who had little knowledge of the ...
(Date:1/20/2017)... ... , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went on to ... published author, Marlyn Ivey, born in Lynn Haven, Florida and at the age of 5, ... years of age, he joined the Navy and got married right out of boot camp. ...
(Date:1/20/2017)... , ... January 20, 2017 , ... ... ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in a study indicating ... Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure Devices ...
(Date:1/20/2017)... ... ... “Journey to Christmas:” a beautiful and enchanting tale that teaches children the true meaning of ... three in Oklahoma City, and a devoted woman of faith. , “Becoming a parent ... the back of my mind for years, but actually doing it might have been a ...
Breaking Medicine News(10 mins):